Compare Public Service Enterprise Group Incorporated Common Stock (PEG) vs Travere Therapeutics Inc. Common Stock (TVTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Public Service Enterprise Group Incorporated Common Stock vs Travere Therapeutics Inc. Common Stock — how do they compare? Public Service Enterprise Group Incorporated Common Stock trades at $69.9 (market cap $35.12B), while Travere Therapeutics Inc. Common Stock trades at $52.74 (market cap $4.88B). The key difference: Public Service Enterprise Group Incorporated Common Stock is far larger — about 7.2× Travere Therapeutics Inc. Common Stock's market cap, and Public Service Enterprise Group Incorporated Common Stock pays a 3.8% dividend while Travere Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Public Service Enterprise Group Incorporated Common Stock for 0 Days and Travere Therapeutics Inc. Common Stock for 0 Days on average.
| PEG | TVTX | |
|---|---|---|
Market Cap | $35.12B | $4.88B |
Volume | 4,400,164 | 1,668,577 |
Sector | Utilities | Health |
52-Week High | $86.95 | $67.52 |
52-Week Low | $66.56 | $26.79 |
Typical Hold Time | 0 Days | 0 Days |
Enterprise Value | $59.61B | $5.01B |
Dividend Yield | 3.8% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Public Service Enterprise Group (PEG) trades at $70.47, down 0.41% on the day, showing neutral technical signals with support at $70 and resistance at $71. The company maintains solid fundamentals with a 17.53 P/E ratio and consistent earnings beats in recent quarters, though Q3 2026 results are pending. Revenue grew to $12.17B in 2025 with a healthy 16.04% net income margin, while analyst consensus remains mixed with a $83.40 price target suggesting potential upside.
PEG presents a stable utility investment with regulated growth and nuclear assets supporting a 6-8% earnings outlook. Key risks include regulatory approvals for capex plans and interest rate sensitivity. Institutional buying and a 15-year dividend growth streak add appeal, but recent CEO stock sales and proximity to 52-week lows warrant caution amid sector volatility.
Travere Therapeutics (TVTX) trades at $51.80, down 0.42% on the day, with a neutral technical signal. The company reported strong revenue growth but persistent net losses, with a 2025 net income margin of -7.35%. Recent news includes new data presentations for its key drug FILSPARI and a CEO transition. Analyst consensus is strongly bullish with an 83.33% buy rating and a $70.60 price target, suggesting significant upside from the current price.
The outlook for TVTX hinges on the commercial success of FILSPARI, which shows promising sales growth, but profitability remains a challenge. Key risks include execution of the CEO transition, competitive pressures in nephrology treatments, and the company's ability to achieve sustained profitability. The high valuation multiples relative to negative earnings present a risk-reward balance for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Public Service Enterprise Group Incorporated Common Stock
Public Service Enterprise Group Incorporated is a New Jersey-based utility holding company operating through Public Service Electric and Gas Co. (PSE&G), which transmits and distributes electricity and distributes natural gas, and PSEG Power, which operates the Salem and Hope Creek nuclear generating stations. It also runs the Long Island Power Authority's electric system under contract via PSEG Long Island.
Read more on PEG →About Travere Therapeutics Inc. Common Stock
Travere Therapeutics Inc. is a biopharmaceutical company focused on rare kidney and metabolic diseases. Its lead product, FILSPARI (sparsentan), is an oral medication for adults with IgA nephropathy, and it also markets Thiola for cystinuria.
Read more on TVTX →
